{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:12:34Z","timestamp":1789157554024,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"DOI":"10.7759\/cureus.116111","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:01:50Z","timestamp":1789156910000},"source":"Crossref","is-referenced-by-count":0,"title":["Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges"],"prefix":"10.7759","author":[{"given":"Tosin","family":"Fakiyesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mmaduabuchi","family":"Ozioko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwapelumi D","family":"Ogunseye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaoluwa","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibukunoluwa","family":"Adedoyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeolu A","family":"Badejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olorungbami","family":"Anifalaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun","family":"Adegbesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwakemi","family":"Olalude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Tiamiyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almustapha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79372","article-title":"The future of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene therapy in cardiomyopathies: a review of its therapeutic potential and emerging applications","volume":"17","author":"Moradi A","year":"2025","unstructured":"Moradi A, Khoshniyat S, Nzeako T, et al.. The future of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene therapy in cardiomyopathies: a review of its therapeutic potential and emerging applications. Cureus. 2025, 17:e79372. 10.7759\/cureus.79372","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.11.003","article-title":"State of gene therapy for monogenic cardiovascular diseases","volume":"99","author":"Bains S","year":"2024","unstructured":"Bains S, Giudicessi JR, Odening KE, Ackerman MJ. State of gene therapy for monogenic cardiovascular diseases. Mayo Clin Proc. 2024, 99:610-629. 10.1016\/j.mayocp.2023.11.003","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5220\/0014493400004933","article-title":"CRISPR-Cas9: a new frontier in the treatment and research of cardiovascular diseases","author":"Jiao J","year":"2025","unstructured":"Jiao J. CRISPR-Cas9: a new frontier in the treatment and research of cardiovascular diseases. Med. 2025, 362-367. 10.5220\/0014493400004933","journal-title":"Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57869","article-title":"The use of CRISPR-Cas9 genetic technology in cardiovascular disease: a comprehensive review of current progress and future prospective","volume":"16","author":"Asif M","year":"2024","unstructured":"Asif M, Khan WJ, Aslam S, Aslam A, Chowdhury MA. The use of CRISPR-Cas9 genetic technology in cardiovascular disease: a comprehensive review of current progress and future prospective. Cureus. 2024, 16:e57869. 10.7759\/cureus.57869","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020131","article-title":"CRISPR-CAS9 in cardiovascular medicine: unlocking new potential for treatment","volume":"14","author":"Bonowicz K","year":"2025","unstructured":"Bonowicz K, Jerka D, Piekarska K, et al.. CRISPR-CAS9 in cardiovascular medicine: unlocking new potential for treatment. Cells. 2025, 14:131. 10.3390\/cells14020131","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2026-0047","article-title":"Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications","volume":"59","author":"Jong U","year":"2026","unstructured":"Jong U, Lim D, Lee SH. Prime editing updates: technological evolution, methodological expansion, and delivery strategies for in vivo applications. BMB Rep. 2026, 59:313-320. 10.5483\/BMBRep.2026-0047","journal-title":"BMB Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.5c00076","article-title":"CRISPR-based regulation for high-throughput screening","volume":"14","author":"Jiao L","year":"2025","unstructured":"Jiao L, Zhou Q, Sun D. CRISPR-based regulation for high-throughput screening. ACS Synth Biol. 2025, 14:1890-1904. 10.1021\/acssynbio.5c00076","journal-title":"ACS Synth Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2026.05.011","article-title":"Emerging frontiers in genome editing: from CRISPR to next-generation technologies","volume":"253","author":"Mishra S","year":"2026","unstructured":"Mishra S, Rehan S, Barekzai AM, Sharma A, Raghav A. Emerging frontiers in genome editing: from CRISPR to next-generation technologies. Methods. 2026, 253:71-84. 10.1016\/j.ymeth.2026.05.011","journal-title":"Methods"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.07.004","article-title":"Progress and challenges towards CRISPR\/Cas clinical translation","volume":"154-155","author":"Rosenblum D","year":"2020","unstructured":"Rosenblum D, Gutkin A, Dammes N, Peer D. Progress and challenges towards CRISPR\/Cas clinical translation. Adv Drug Deliv Rev. 2020, 154-155:176-186. 10.1016\/j.addr.2020.07.004","journal-title":"Adv Drug Deliv Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1039\/d5na00535c","article-title":"Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond","volume":"8","author":"Bharti N","year":"2026","unstructured":"Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026, 8:1137-1161. 10.1039\/d5na00535c","journal-title":"Nanoscale Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2601283","article-title":"In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia","volume":"395","author":"Vafai SB","year":"2026","unstructured":"Vafai SB, T\u00e4ubel J, Ashdown T, et al.. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N Engl J Med. 2026, 395:648-659. 10.1056\/NEJMoa2601283","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000001087","article-title":"Clustered regularly interspaced short palindromic repeats genome editing for cardiovascular disease: the future is here","author":"Sami N","year":"2025","unstructured":"Sami N, Parikh MA, Frishman WH, Peterson SJ. Clustered regularly interspaced short palindromic repeats genome editing for cardiovascular disease: the future is here. Cardiol Rev. 2025, 10.1097\/CRD.0000000000001087","journal-title":"Cardiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen R","year":"2002","unstructured":"Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002, 43:1565-1575. 10.1046\/j.1365-2958.2002.02839.x","journal-title":"Mol Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297922080090","article-title":"CRISPR-Cas9: a history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya I","year":"2022","unstructured":"Gostimskaya I. CRISPR-Cas9: a history of its discovery and ethical considerations of its use in genome editing. Biochemistry (Mosc). 2022, 87:777-788. 10.1134\/S0006297922080090","journal-title":"Biochemistry (Mosc)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2021.0120","article-title":"On-target adverse events of CRISPR-Cas9 nuclease: more chaotic than expected","volume":"5","author":"Boutin J","year":"2022","unstructured":"Boutin J, Cappellen D, Rosier J, Amintas S, Dabernat S, Bedel A, Moreau-Gaudry F. On-target adverse events of CRISPR-Cas9 nuclease: more chaotic than expected. CRISPR J. 2022, 5:19-30. 10.1089\/crispr.2021.0120","journal-title":"CRISPR J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali P","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, et al.. RNA-guided human genome engineering via Cas9. Science. 2013, 339:823-826. 10.1126\/science.1232033","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor AC","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016, 533:420-424. 10.1038\/nature17946","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00669-3","article-title":"The use of new CRISPR tools in cardiovascular research and medicine","volume":"19","author":"Nishiga M","year":"2022","unstructured":"Nishiga M, Liu C, Qi LS, Wu JC. The use of new CRISPR tools in cardiovascular research and medicine. Nat Rev Cardiol. 2022, 19:505-521. 10.1038\/s41569-021-00669-3","journal-title":"Nat Rev Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2021.664997","article-title":"Base editing in plants: applications, challenges, and future prospects","volume":"12","author":"Azameti MK","year":"2021","unstructured":"Azameti MK, Dauda WP. Base editing in plants: applications, challenges, and future prospects. Front Plant Sci. 2021, 12:664997. 10.3389\/fpls.2021.664997","journal-title":"Front Plant Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-026-00478-3","article-title":"Precision genome editing with DNA base editors","volume":"6","author":"Mawson SJ","year":"2026","unstructured":"Mawson SJ, Dunne-Dombrink K, Komor AC. Precision genome editing with DNA base editors. Nat Rev Methods Primers. 2026, 6:2662-8449. 10.1038\/s43586-026-00478-3","journal-title":"Nat Rev Methods Primers"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01821-9","article-title":"Adenine transversion editors enable precise, efficient A\u2022T-to-C\u2022G base editing in mammalian cells and embryos","volume":"42","author":"Chen L","year":"2024","unstructured":"Chen L, Hong M, Luan C, et al.. Adenine transversion editors enable precise, efficient A\u2022T-to-C\u2022G base editing in mammalian cells and embryos. Nat Biotechnol. 2024, 42:638-650. 10.1038\/s41587-023-01821-9","journal-title":"Nat Biotechnol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.10.002","article-title":"Genome editing: the recent history and perspective in cardiovascular diseases","volume":"70","author":"Musunuru K","year":"2017","unstructured":"Musunuru K. Genome editing: the recent history and perspective in cardiovascular diseases. J Am Coll Cardiol. 2017, 70:2808-2821. 10.1016\/j.jacc.2017.10.002","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone AV","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020, 38:824-844. 10.1038\/s41587-020-0561-9","journal-title":"Nat Biotechnol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-scale CRISPR-mediated control of gene repression and activation","volume":"159","author":"Gilbert LA","year":"2014","unstructured":"Gilbert LA, Horlbeck MA, Adamson B, et al.. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014, 159:647-661. 10.1016\/j.cell.2014.09.029","journal-title":"Cell"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone AV","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, et al.. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019, 576:149-157. 10.1038\/s41586-019-1711-4","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1039315","article-title":"Current advancement in the application of prime editing","volume":"11","author":"Huang Z","year":"2023","unstructured":"Huang Z, Liu G. Current advancement in the application of prime editing. Front Bioeng Biotechnol. 2023, 11:1039315. 10.3389\/fbioe.2023.1039315","journal-title":"Front Bioeng Biotechnol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02304-3","article-title":"Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression","volume":"22","author":"Gao P","year":"2021","unstructured":"Gao P, Lyu Q, Ghanam AR, et al.. Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression. Genome Biol. 2021, 22:83. 10.1186\/s13059-021-02304-3","journal-title":"Genome Biol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi LS","year":"2013","unstructured":"Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013, 152:1173-1183. 10.1016\/j.cell.2013.02.022","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann S","year":"2015","unstructured":"Konermann S, Brigham MD, Trevino AE, et al.. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015, 517:583-588. 10.1038\/nature14136","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.03.004","article-title":"Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline","volume":"24","author":"Hershberger RE","year":"2018","unstructured":"Hershberger RE, Givertz MM, Ho CY, et al.. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail. 2018, 24:281-302. 10.1016\/j.cardfail.2018.03.004","journal-title":"J Card Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm AC","year":"2018","unstructured":"Sturm AC, Knowles JW, Gidding SS, et al.. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018, 72:662-680. 10.1016\/j.jacc.2018.05.044","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00643-0","article-title":"Hypertrophic cardiomyopathy","volume":"11","author":"Argir\u00f2 A","year":"2025","unstructured":"Argir\u00f2 A, Parikh V, Jurcut R, Finocchiaro G, Kaski JP, Adler E, Olivotto I. Hypertrophic cardiomyopathy. Nat Rev Dis Primers. 2025, 11:58. 10.1038\/s41572-025-00643-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00608-2","article-title":"Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies","volume":"19","author":"Walsh R","year":"2022","unstructured":"Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol. 2022, 19:151-167. 10.1038\/s41569-021-00608-2","journal-title":"Nat Rev Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.053033","article-title":"Evidence-based assessment of genes in dilated cardiomyopathy","volume":"144","author":"Jordan E","year":"2021","unstructured":"Jordan E, Peterson L, Ai T, et al.. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021, 144:7-19. 10.1161\/CIRCULATIONAHA.120.053033","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab355","article-title":"Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: new predictors for left-sided variants?","volume":"42","author":"Corrado D","year":"2021","unstructured":"Corrado D, Migliore F, Zorzi A. Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: new predictors for left-sided variants?. Eur Heart J. 2021, 42:2851-2853. 10.1093\/eurheartj\/ehab355","journal-title":"Eur Heart J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061093","article-title":"Exploring the potential of symmetric exon deletion to treat Non-Ischemic dilated cardiomyopathy by removing frameshift mutations in TTN","volume":"13","author":"Rodriguez-Polo I","year":"2022","unstructured":"Rodriguez-Polo I, Behr R. Exploring the potential of symmetric exon deletion to treat Non-Ischemic dilated cardiomyopathy by removing frameshift mutations in TTN. Genes (Basel). 2022, 13:10.3390\/genes13061093","journal-title":"Genes (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2025.06.002","article-title":"Updates on inherited arrhythmia syndromes (Brugada syndrome, long QT syndrome, CPVT, ARVC)","volume":"91","author":"Moore BM","year":"2025","unstructured":"Moore BM, Roston TM, Laksman Z, Krahn AD. Updates on inherited arrhythmia syndromes (Brugada syndrome, long QT syndrome, CPVT, ARVC). Prog Cardiovasc Dis. 2025, 91:130-143. 10.1016\/j.pcad.2025.06.002","journal-title":"Prog Cardiovasc Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-023-01797-w","article-title":"Current gaps in knowledge in inherited arrhythmia syndromes","volume":"31","author":"Peltenburg PJ","year":"2023","unstructured":"Peltenburg PJ, Crotti L, Roston TM, van der Werf C. Current gaps in knowledge in inherited arrhythmia syndromes. Neth Heart J. 2023, 31:272-281. 10.1007\/s12471-023-01797-w","journal-title":"Neth Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.078","article-title":"Interplay between genetic substrate, QTC duration, and arrhythmia risk in patients with long QT syndrome","volume":"71","author":"Mazzanti A","year":"2018","unstructured":"Mazzanti A, Maragna R, Vacanti G, et al.. Interplay between genetic substrate, QTC duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol. 2018, 71:1663-1671. 10.1016\/j.jacc.2018.01.078","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao H","year":"2020","unstructured":"Zhao H, Li Y, He L, et al.. In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020, 141:67-79. 10.1161\/CIRCULATIONAHA.119.042476","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01198-3","article-title":"Gene editing for the treatment of hypercholesterolemia","volume":"26","author":"Hoekstra M","year":"2024","unstructured":"Hoekstra M, Van Eck M. Gene editing for the treatment of hypercholesterolemia. Curr Atheroscler Rep. 2024, 26:139-146. 10.1007\/s11883-024-01198-3","journal-title":"Curr Atheroscler Rep"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04254-4","article-title":"In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial","volume":"32","author":"Wan P","year":"2026","unstructured":"Wan P, Tang S, Lin D, et al.. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat Med. 2026, 32:1045-1051. 10.1038\/s41591-026-04254-4","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai AC","year":"2023","unstructured":"Chai AC, Cui M, Chemello F, et al.. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023, 29:401-411. 10.1038\/s41591-022-02176-5","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00384-3","article-title":"Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy","volume":"30","author":"Nie J","year":"2023","unstructured":"Nie J, Han Y, Jin Z, et al.. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. Gene Ther. 2023, 30:520-527. 10.1038\/s41434-023-00384-3","journal-title":"Gene Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.omta.2025.201653","article-title":"CRISPR-mediated targeting of the LMNA c.745C>T mutation enhances survival and cardiac function in congenital muscular dystrophy","volume":"34","author":"G\u00f3mez-Dom\u00ednguez D","year":"2026","unstructured":"G\u00f3mez-Dom\u00ednguez D, Epifano C, Hern\u00e1ndez I, et al.. CRISPR-mediated targeting of the LMNA c.745C>T mutation enhances survival and cardiac function in congenital muscular dystrophy. Mol Ther Adv. 2026, 34:201653. 10.1016\/j.omta.2025.201653","journal-title":"Mol Ther Adv"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.065624","article-title":"In vivo base editing of Scn5a rescues type 3 long QT syndrome in mice","volume":"149","author":"Qi M","year":"2024","unstructured":"Qi M, Ma S, Liu J, et al.. In vivo base editing of Scn5a rescues type 3 long QT syndrome in mice. Circulation. 2024, 149:317-329. 10.1161\/CIRCULATIONAHA.123.065624","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313369","article-title":"In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia","volume":"123","author":"Pan X","year":"2018","unstructured":"Pan X, Philippen L, Lahiri SK, et al.. In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2018, 123:953-963. 10.1161\/CIRCRESAHA.118.313369","journal-title":"Circ Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320496","article-title":"CRISPR modeling and correction of cardiovascular disease","volume":"130","author":"Liu N","year":"2022","unstructured":"Liu N, Olson EN. CRISPR modeling and correction of cardiovascular disease. Circ Res. 2022, 130:1827-1850. 10.1161\/CIRCRESAHA.122.320496","journal-title":"Circ Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.02.003","article-title":"Therapeutic genome editing in cardiovascular diseases","volume":"168","author":"Nishiga M","year":"2021","unstructured":"Nishiga M, Qi LS, Wu JC. Therapeutic genome editing in cardiovascular diseases. Adv Drug Deliv Rev. 2021, 168:147-157. 10.1016\/j.addr.2020.02.003","journal-title":"Adv Drug Deliv Rev"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03592-1","article-title":"Gene editing and cardiac disease modelling for the interpretation of genetic variants of uncertain significance in congenital heart disease","volume":"14","author":"Fear VS","year":"2023","unstructured":"Fear VS, Forbes CA, Shaw NC, et al.. Gene editing and cardiac disease modelling for the interpretation of genetic variants of uncertain significance in congenital heart disease. Stem Cell Res Ther. 2023, 14:345. 10.1186\/s13287-023-03592-1","journal-title":"Stem Cell Res Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321951","article-title":"iPSC-based modeling of variable clinical presentation in hypertrophic cardiomyopathy","volume":"133","author":"Escrib\u00e1 R","year":"2023","unstructured":"Escrib\u00e1 R, Larra\u00f1aga-Moreira JM, Richaud-Patin Y, et al.. iPSC-based modeling of variable clinical presentation in hypertrophic cardiomyopathy. Circ Res. 2023, 133:108-119. 10.1161\/CIRCRESAHA.122.321951","journal-title":"Circ Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02964-3","article-title":"KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation","volume":"13","author":"Song Y","year":"2022","unstructured":"Song Y, Guo T, Jiang Y, et al.. KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation. Stem Cell Res Ther. 2022, 13:287. 10.1186\/s13287-022-02964-3","journal-title":"Stem Cell Res Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101357","article-title":"CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability","volume":"16","author":"He Y","year":"2026","unstructured":"He Y, Tu X, Xue Y, et al.. CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. J Pharm Anal. 2026, 16:101357. 10.1016\/j.jpha.2025.101357","journal-title":"J Pharm Anal"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081103","article-title":"CRISPR-Cas system: the current and emerging translational landscape","volume":"12","author":"Bhokisham N","year":"2023","unstructured":"Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas system: the current and emerging translational landscape. Cells. 2023, 12:1103. 10.3390\/cells12081103","journal-title":"Cells"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.25258\/ijddt.16.10s.22","article-title":"Gene editing strategies (CRISPR) for inherited cardiomyopathies: ethical, technical and clinical review","volume":"16","author":"Amritkumar P","year":"2026","unstructured":"Amritkumar P, Jayannan, Prabhavathi DN, Kavitha M, Pugazhendhi S, Divya N. Gene editing strategies (CRISPR) for inherited cardiomyopathies: ethical, technical and clinical review. Int J Drug Deliv Technol. 2026, 16:150-154. 10.25258\/ijddt.16.10s.22","journal-title":"Int J Drug Deliv Technol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.025","article-title":"Clinical effect of genetic testing in inherited cardiovascular diseases: a 14-year retrospective study","volume":"85","author":"Grondin S","year":"2025","unstructured":"Grondin S, Neveu B, Soltani I, et al.. Clinical effect of genetic testing in inherited cardiovascular diseases: a 14-year retrospective study. J Am Coll Cardiol. 2025, 85:988-999. 10.1016\/j.jacc.2024.11.025","journal-title":"J Am Coll Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.synbio.2025.10.003","article-title":"CRISPy-web 3.0: a unified platform for multi-modal guide RNA design for CRISPR and TnpB genome editing applications","volume":"11","author":"Yang S","year":"2026","unstructured":"Yang S, Cai Z, Chia N, Luo J, Weber T, Blin K, Tong Y. CRISPy-web 3.0: a unified platform for multi-modal guide RNA design for CRISPR and TnpB genome editing applications. Synth Syst Biotechnol. 2026, 11:317-322. 10.1016\/j.synbio.2025.10.003","journal-title":"Synth Syst Biotechnol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.02.007","article-title":"Gene Editing of Human Embryos with CRISPR\/Cas9: Great Promise Coupled with Important Caveats","volume":"26","author":"Schenkwein D","year":"2018","unstructured":"Schenkwein D, Yl\u00e4-Herttuala S. Gene Editing of Human Embryos with CRISPR\/Cas9: Great Promise Coupled with Important Caveats. Mol Ther. 2018, 26:659-660. 10.1016\/j.ymthe.2018.02.007","journal-title":"Mol Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart D","year":"2023","unstructured":"Reichart D, Newby GA, Wakimoto H, et al.. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023, 29:412-421. 10.1038\/s41591-022-02190-7","journal-title":"Nat Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3079","article-title":"Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations","volume":"13","author":"Fomin A","year":"2021","unstructured":"Fomin A, G\u00e4rtner A, Cyganek L, et al.. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci Transl Med. 2021, 13:eabd3079. 10.1126\/scitranslmed.abd3079","journal-title":"Sci Transl Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2061","article-title":"Modulating TTN gene expression in human iPSC-CMs to investigate mechanisms and therapies in TTN-associated dilated cardiomyopathy","volume":"45","author":"Kirk RB","year":"2024","unstructured":"Kirk RB, Sparrow AJ, Hooper C. Modulating TTN gene expression in human iPSC-CMs to investigate mechanisms and therapies in TTN-associated dilated cardiomyopathy. European Heart J. 2024, 45:10.1093\/eurheartj\/ehae666.2061","journal-title":"European Heart J"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39352-1","article-title":"Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy","volume":"14","author":"Grosch M","year":"2023","unstructured":"Grosch M, Schraft L, Chan A, et al.. Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat Commun. 2023, 14:3714. 10.1038\/s41467-023-39352-1","journal-title":"Nat Commun"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama T","year":"2022","unstructured":"Nishiyama T, Zhang Y, Cui M, et al.. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci Transl Med. 2022, 14:eade1633. 10.1126\/scitranslmed.ade1633","journal-title":"Sci Transl Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/circ.146.suppl_1.13927","article-title":"Abstract 13927: AAV gene therapy to treat underlying cardiac biomechanical defects in LMNA dilated cardiomyopathy improves lifespan and preserves ejection fraction in LMNA DCM mouse model","volume":"146","author":"Werner H","year":"2022","unstructured":"Werner H, Gan ES, Loh CY, et al.. Abstract 13927: AAV gene therapy to treat underlying cardiac biomechanical defects in LMNA dilated cardiomyopathy improves lifespan and preserves ejection fraction in LMNA DCM mouse model. Circulation. 2022, 146:A13927. 10.1161\/circ.146.suppl_1.13927","journal-title":"Circulation"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1161\/circ.152.suppl_3.4369891","article-title":"Abstract 4369891: modeling the early effects of a novel intronic LMNA mutation in iPSC-derived 3D cardiac organoids","volume":"152","author":"Zuniga A","year":"2025","unstructured":"Zuniga A, Dulce R, Asensi K, et al.. Abstract 4369891: modeling the early effects of a novel intronic LMNA mutation in iPSC-derived 3D cardiac organoids. Circulation . 2025, 152:A4369891. 10.1161\/circ.152.suppl_3.4369891","journal-title":"Circulation"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1161\/circ.152.suppl_3.4373020","article-title":"Abstract 4373020: CRISPR-corrected iPSC models of pediatric LMNA cardiomyopathy: A meta-analysis of preclinical translational outcomes","volume":"152","author":"Kumar H","year":"2025","unstructured":"Kumar H, Kumari S, Tiwari A. Abstract 4373020: CRISPR-corrected iPSC models of pediatric LMNA cardiomyopathy: A meta-analysis of preclinical translational outcomes. Circulation. 2025, 152:A4373020. 10.1161\/circ.152.suppl_3.4373020","journal-title":"Circulation"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.318069","article-title":"Is it ever wise to edit wild-type alleles? Engineered CRISPR alleles versus millions of years of human evolution","volume":"44","author":"Kozan DW","year":"2024","unstructured":"Kozan DW, Farber SA. Is it ever wise to edit wild-type alleles? Engineered CRISPR alleles versus millions of years of human evolution. Arterioscler Thromb Vasc Biol. 2024, 44:328-333. 10.1161\/ATVBAHA.123.318069","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121648","article-title":"A review of progress on targeting LDL receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ASCVD","volume":"12","author":"Srivastava RA","year":"2023","unstructured":"Srivastava RA. A review of progress on targeting LDL receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ASCVD. Cells. 2023, 12:1648. 10.3390\/cells12121648","journal-title":"Cells"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01036-0","article-title":"Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice","volume":"13","author":"Zuo Y","year":"2023","unstructured":"Zuo Y, Zhang C, Zhou Y, et al.. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. Cell Biosci. 2023, 13:109. 10.1186\/s13578-023-01036-0","journal-title":"Cell Biosci"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2508286","article-title":"Therapeutic gene editing in dyslipidemias","volume":"25","author":"Tamehri Zadeh SS","year":"2024","unstructured":"Tamehri Zadeh SS, Shapiro MD. Therapeutic gene editing in dyslipidemias. Rev Cardiovasc Med. 2024, 25:286. 10.31083\/j.rcm2508286","journal-title":"Rev Cardiovasc Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1475152","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions","volume":"15","author":"Joshi J","year":"2024","unstructured":"Joshi J, Albers C, Smole N, Guo S, Smith SA. Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions. Front Physiol. 2024, 15:1475152. 10.3389\/fphys.2024.1475152","journal-title":"Front Physiol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034690","article-title":"Defining cardiomyocyte repolarization response to pharmacotherapy in long-QT syndrome type 3","volume":"13","author":"Ge N","year":"2024","unstructured":"Ge N, Li R, Liu M, et al.. Defining cardiomyocyte repolarization response to pharmacotherapy in long-QT syndrome type 3. J Am Heart Assoc. 2024, 13:e034690. 10.1161\/JAHA.124.034690","journal-title":"J Am Heart Assoc"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051836","article-title":"Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome","volume":"143","author":"Dotzler SM","year":"2021","unstructured":"Dotzler SM, Kim CS, Gendron WA, et al.. Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome. Circulation. 2021, 143:1411-1425. 10.1161\/CIRCULATIONAHA.120.051836","journal-title":"Circulation"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051153","article-title":"hiPSC-derived cardiomyocyte model of LQT2 syndrome derived from asymptomatic and symptomatic mutation carriers reproduces clinical differences in aggregates but not in single cells","volume":"9","author":"Shah D","year":"2020","unstructured":"Shah D, Prajapati C, Penttinen K, et al.. hiPSC-derived cardiomyocyte model of LQT2 syndrome derived from asymptomatic and symptomatic mutation carriers reproduces clinical differences in aggregates but not in single cells. Cells. 2020, 9:1153. 10.3390\/cells9051153","journal-title":"Cells"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52871-1","article-title":"Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues","volume":"14","author":"T. L. Maurissen","year":"2024","unstructured":"T. L. Maurissen, M. Kawatou, V. L\u00f3pez-D\u00e1vila. Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues. Scientific Reports. 2024, 14:10.1038\/s41598-024-52871-1","journal-title":"Scientific Reports"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-009-0761-0","article-title":"Cardiac sodium channelopathies","volume":"460","author":"Amin AS","year":"2010","unstructured":"Amin AS, Asghari-Roodsari A, Tan HL. Cardiac sodium channelopathies. Pflugers Arch. 2010, 460:223-237. 10.1007\/s00424-009-0761-0","journal-title":"Pflugers Arch"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325330","article-title":"Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: a scoping review","volume":"20","author":"Vo QD","year":"2025","unstructured":"Vo QD. Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: a scoping review. PLoS One. 2025, 20:e0325330. 10.1371\/journal.pone.0325330","journal-title":"PLoS One"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.123","article-title":"Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat","volume":"19","author":"Bish LT","year":"2008","unstructured":"Bish LT, Morine K, Sleeper MM, et al.. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008, 19:1359-1368. 10.1089\/hum.2008.123","journal-title":"Hum Gene Ther"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-370-7_6","article-title":"AAV-mediated liver-directed gene therapy","volume":"807","author":"Sands MS","year":"2011","unstructured":"Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011, 807:141-157. 10.1007\/978-1-61779-370-7_6","journal-title":"Methods Mol Biol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera H","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020, 28:723-746. 10.1016\/j.ymthe.2019.12.010","journal-title":"Mol Ther"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung HN","year":"2022","unstructured":"Jung HN, Lee SY, Lee S, Youn H, Im HJ. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging. Theranostics. 2022, 12:7509-7531. 10.7150\/thno.77259","journal-title":"Theranostics"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.4c00816","article-title":"Building the future of clinical diagnostics: an analysis of potential benefits and current barriers in CRISPR\/Cas diagnostics","volume":"14","author":"van Dongen JE","year":"2025","unstructured":"van Dongen JE, Segerink LI. Building the future of clinical diagnostics: an analysis of potential benefits and current barriers in CRISPR\/Cas diagnostics. ACS Synth Biol. 2025, 14:323-331. 10.1021\/acssynbio.4c00816","journal-title":"ACS Synth Biol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1159\/000547334","article-title":"Challenges and opportunities in the application of CRISPR-CAS9: a review on genomic editing and therapeutic potentials","volume":"35","author":"Karimi MA","year":"2026","unstructured":"Karimi MA, Paryan M, Behrouzian Fard G, Sadeghian H, Zarrinfar H, Hosseini BM. Challenges and opportunities in the application of CRISPR-CAS9: a review on genomic editing and therapeutic potentials. Med Princ Pract. 2026, 35:1-17. 10.1159\/000547334","journal-title":"Med Princ Pract"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2026.04.014","article-title":"Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation","volume":"33","author":"Lei L","year":"2026","unstructured":"Lei L, Kaufmann MM, Lao J, et al.. Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation. Cell Stem Cell. 2026, 33:930.e5-944.e5. 10.1016\/j.stem.2026.04.014","journal-title":"Cell Stem Cell"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202402630","article-title":"Exploring the potential and challenges of CRISPR delivery and therapeutics for genetic disease treatment","volume":"34","author":"Yang X","year":"2024","unstructured":"Yang X, Bui TA, Mei H. Exploring the potential and challenges of CRISPR delivery and therapeutics for genetic disease treatment. Adv Funct Mater. 2024, 34:2402630. 10.1002\/adfm.202402630","journal-title":"Adv Funct Mater"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.005","article-title":"A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver","volume":"30","author":"Zheng C","year":"2022","unstructured":"Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022, 30:1343-1351. 10.1016\/j.ymthe.2022.01.005","journal-title":"Mol Ther"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.synbio.2025.03.007","article-title":"Optimized dual-AAV base editor delivery system with enhanced editing efficiency and virion production titer","volume":"10","author":"Yu W","year":"2025","unstructured":"Yu W, Wang Y, Li S, et al.. Optimized dual-AAV base editor delivery system with enhanced editing efficiency and virion production titer. Synth Syst Biotechnol. 2025, 10:697-706. 10.1016\/j.synbio.2025.03.007","journal-title":"Synth Syst Biotechnol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu W","year":"2021","unstructured":"Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021, 4:179-191. 10.1093\/pcmedi\/pbab014","journal-title":"Precis Clin Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.760140","article-title":"Gene therapy for cardiovascular Disease: Basic research and clinical prospects","volume":"8","author":"Cao G","year":"2021","unstructured":"Cao G, Xuan X, Zhang R, Hu J, Dong H. Gene therapy for cardiovascular Disease: Basic research and clinical prospects. Front Cardiovasc Med. 2021, 8:760140. 10.3389\/fcvm.2021.760140","journal-title":"Front Cardiovasc Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.18699\/vjgb-25-38","article-title":"Generation of the ICGi019-B-1 and ICGi019-B-2 lines via correction of the p.Met659Ile (c.1977G>A) variant in MYH7 of patient-specific induced pluripotent stem cells using CRISPR\/Cas9","volume":"29","author":"Shulgina AE","year":"2025","unstructured":"Shulgina AE, Pavlova SV, Minina JM, Zakian SM, Dementyeva EV. Generation of the ICGi019-B-1 and ICGi019-B-2 lines via correction of the p.Met659Ile (c.1977G>A) variant in MYH7 of patient-specific induced pluripotent stem cells using CRISPR\/Cas9. Vavilovskii Zhurnal Genet Selektsii. 2025, 29:349-357. 10.18699\/vjgb-25-38","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.25258\/ijddt.15.1.46","article-title":"CRISPR\/CAS9 and gene editing in drug delivery: emerging delivery systems for gene therapy and genome","volume":"15","author":"Patil GR","year":"2025","unstructured":"Patil GR, Varma SK. CRISPR\/CAS9 and gene editing in drug delivery: emerging delivery systems for gene therapy and genome. Int J Drug Deliv Technol. 2025, 15:335-341. 10.25258\/ijddt.15.1.46","journal-title":"Int J Drug Deliv Technol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01462-9","article-title":"Revolutionizing CRISPR technology with artificial intelligence","volume":"57","author":"Kim MG","year":"2025","unstructured":"Kim MG, Go MJ, Kang SH, Jeong SH, Lim K. Revolutionizing CRISPR technology with artificial intelligence. Exp Mol Med. 2025, 57:1419-1431. 10.1038\/s12276-025-01462-9","journal-title":"Exp Mol Med"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149938","article-title":"CRISPR 2.0: expanding the genome engineering Toolbox for epigenetics, RNA editing, and molecular diagnostics","volume":"979","author":"Pradhan K","year":"2026","unstructured":"Pradhan K, Anoop S. CRISPR 2.0: expanding the genome engineering Toolbox for epigenetics, RNA editing, and molecular diagnostics. Gene. 2026, 979:149938. 10.1016\/j.gene.2025.149938","journal-title":"Gene"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514525-clustered-regularly-interspaced-short-palindromic-repeats-crispr-based-genome-editing-in-inherited-cardiovascular-diseases-therapeutic-advances-emerging-editing-platforms-and-translational-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:01:51Z","timestamp":1789156911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514525-clustered-regularly-interspaced-short-palindromic-repeats-crispr-based-genome-editing-in-inherited-cardiovascular-diseases-therapeutic-advances-emerging-editing-platforms-and-translational-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":93,"URL":"https:\/\/doi.org\/10.7759\/cureus.116111","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}